|Day Low/High||43.64 / 44.15|
|52 Wk Low/High||36.15 / 51.55|
Nobody in AbbVie right now is in it for the past performance.
For those who love a roll of the dice, GNPX may be worth a closer look.
These healthcare stalwarts look attractive for growth and income.
These stocks are priced for total imperfection. That's just what you want.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...
What trader has never both fallen in love with Nvidia, only to eventually feel the scorn of an angry lover's tortured vengeance?
These companies are working to plant their flag in a new landscape.
One of pharma's biggest CEO's talks M&A action on the exchange.
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
This at-the-money, long put shooter is a high risk trade, so use discretionary capital.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.
I continue to see these names as bargains in the biotech and biopharma space.
These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.
Data and industry conferences will likely be catalysts for shares in the space.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Surviving the age of Amazon is all there is to retailers' earnings.